Taking advantage of an improved outlook for gene therapy, Oxford BioMedica Plc is proposing to raise up to £25.7 million in a private share placement and open offer to investors to finance development of its gene-based ophthalmology portfolio and manufacturing activities.
ArGEN-X BV has entered into a strategic antibody alliance with Shire Plc aimed at helping that company discover new therapeutics aligned with its focus on rare diseases. The new alliance follows a successful discovery collaboration between the two companies that started in 2012.
The UK cell-therapy company Adaptimmune Ltd has entered a collaboration with GlaxoSmithKline Plc to advance the development of an autologous T-cell receptor product for patients with a variety of cancers.
Imperial Innovations Plc has announced plans to raise up £150 million by way of a private share placement with existing and new institutional investors in order to support the financing needs of its portfolio companies and to source new investment opportunities.
Rodin Therapeutics Inc of the US has raised $12.9 million in Series A money from its founding investors in order to advance its pipeline of candidate drugs directed against epigenetic targets for neurological disorders. The company is based on German drug discovery technology.
ArGEN-X BV has secured a collaboration with Bayer AG to discover and develop candidate therapeutic antibodies directed at a number of targets across multiple therapeutic areas that, it says, are often intractable to existing antibody platforms.
Evotec AG has expanded its drug discovery services into the area of infectious disease with the acquisition of the UK contract research organisation Euprotec Ltd. Euprotec has a portfolio of assays that can be used to discover treatments for bacterial and fungal diseases.
A spin-out from a German government-funded incubator has produced technology for potentially delivering drugs across the blood-brain barrier. The spin-out, Neuway Pharma GmbH, has now received €2.7 million in an A financing round led by Wellington Partners.
There have always been regional discrepancies in the way capital markets operate. But only recently have the differences in the valuations of life science companies in the US and Europe been such a big topic for discussion. This was in full display at the 2014 BioTrinity meeting held in London on 12-14 May,
Pfizer Inc said it won’t pursue its nearly £70 billion bid for AstraZeneca Plc in light of the UK company’s rejection of its final offer on 19 May. The statement came just hours before the legal period for a final deal expired under UK takeover rules.